Addressing a broad range of chronic diseases
Our Shielded Living TherapeuticsTM platform combines advanced cell engineering with innovations in biocompatible materials, potentially enabling our products to produce a wide range of therapeutic molecules that may be missing or deficient in the body, including proteins, antibodies and enzymes.
Our pipeline currently spans three disease areas – including rare blood, lysosomal storage, and endocrine diseases – with product candidates designed to be off-the-shelf, durable, controllable and redosable, without requiring modification of the patient’s genes or immunosuppression.
Based on earlier preclinical data, we believe that SIG-001, our lead product candidate, has the potential to prevent bleeding episodes in patients with moderate-severe to severe hemophilia A by continuously secreting human FVIII. We are currently enrolling patients in a Phase 1/2 trial in this indication, as we continue to advance our other programs toward the clinic.
|Program||Discovery||Lead Optimization||IND Enabling||Phase 1/2||Phase 3|
|Rare Blood Disorders|
|SIG-001 - Hemophilia A*||
|SIG-009 - FVII Deficiency||
|SIG-003 - Hemophilia B||
|Lysosomal Storage Diseases|
|SIG-005 - MPS-1||
|SIG-007 - Fabry||
|SIG-018 - MPS-2||
|Endocrine & Other Chronic Diseases|
|SIG-002 - Type 1 Diabetes**||
|SIG-014 - Wet AMD||
|SIG-015 - Immune-Mediated Diseases||
*IND and CTA cleared.
**Sigilon is leading execution of the program through IND and Eli Lilly and Company (Lilly), a global leader in diabetes, will develop and commercialize the program worldwide.